H.R. 8551: Early Access to Screening Act

This bill, known as the Early Access to Screening Act, proposes changes to the healthcare coverage for annual screening mammograms for women.

Key Provisions

• No-Cost Coverage for Mammograms: The bill mandates that starting January 1, 2026, all women aged 30 and older will receive annual screening mammograms at no cost under Medicare and Medicaid programs. This means that there will be no out-of-pocket expenses for women in this age group for these specific screenings.
• Inclusion in Medicare: The legislation amends existing provisions of the Social Security Act to ensure that Medicare covers these screenings without requiring anyone to pay any costs associated with the exams.
• Inclusion in Medicaid: The bill also requires that state Medicaid programs provide coverage for annual mammograms for women over the age of 29 without any cost-sharing requirements, ensuring access to these health services for lower-income individuals.
• Coverage Under Private Insurance: The law would extend similar no-cost coverage requirements for annual mammograms to group and individual health insurance plans, ensuring that all women over 29 are provided this benefit without cost-sharing provisions.

Specifics of Coverage

• Mammograms will be covered for women who are 30 years of age and older.
• Women under 30 will not be covered for these screenings.
• Women aged 30 and older must wait at least 11 months after a previous screening before they can receive another mammogram covered by Medicare.

Implementation Timeline

The provisions for no-cost coverage for mammograms will take effect on January 1, 2026, for all the programs mentioned in the bill. This is aimed at ensuring that when the law is applied, women can easily access these crucial health screenings without having to worry about the costs involved.

Impact on Health Insurance Plans

The bill makes it mandatory for private health insurance plans to include this annual mammography coverage without cost-sharing. This ensures that affecting millions of women will have access to preventive health services that can lead to early detection of breast cancer.

Relevant Companies

• MRK - Merck & Co., Inc.: As a major pharmaceutical company, Merck could see changes in patient management and treatment practices related to breast cancer, potentially affecting their product offerings.
• PFE - Pfizer Inc.: Pfizer, known for its contributions to oncology care, may need to adjust its marketing and distribution strategies in light of increased screening rates and consequent patient needs.